|
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) |
|
Biocryst Pharmaceuticals Inc
BCRX's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Biocryst Pharmaceuticals Inc growth rates, revenue grew
by 56.89 % in the first quarter of 2025 from the same quarter a year ago.
Ranking at No. 485
Biotechnology & Pharmaceuticals industry recorded
growth of revenues by 10.32 %
Biocryst Pharmaceuticals Inc realized net income compared to net loss a year ago in first quarter of 2025
• More on BCRX's Growth
|
|
Biocryst Pharmaceuticals Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 104.36 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 4.3.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.87.
• More on BCRX's Valuation
|
|
|
|
|
Biocryst Pharmaceuticals Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 104.36 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 4.3.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.87.
• More on BCRX's Valuation
|
|
BCRX's Profitability Comparisons
|
Biocryst Pharmaceuticals Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in first quarter of 2025 to 14.59 %.
Biocryst Pharmaceuticals Inc net profit margin of 0.02 % is currently ranking no. 15 in Biotechnology & Pharmaceuticals industry, ranking no. 141 in Healthcare sector and number 1638 in S&P 500.
Profitability by Segment |
Total |
0.02 % |
|
|
Biocryst Pharmaceuticals Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in first quarter of 2025 to 14.59 %.
Biocryst Pharmaceuticals Inc net profit margin of 0.02 % is currently ranking no. 15 in Biotechnology & Pharmaceuticals industry, ranking no. 141 in Healthcare sector and number 1638 in S&P 500.
• More on BCRX's Key Ratios
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com